- Home
- BMHL vs CNTB Comparison
BMHL vs CNTB Comparison
Compare BMHL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMHL | CNTB |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 140.4M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMHL | CNTB |
|---|---|---|
| Price | $3.50 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.88 |
| AVG Volume (30 Days) | 6.3K | ★ 2.0M |
| Earning Date | 03-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $11,291.47 |
| Revenue Next Year | N/A | $74.30 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.85 |
| 52 Week High | $6.35 | $3.82 |
Technical Indicators
Market Signals| Indicator | BMHL | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 26.62 | 38.76 |
| Support Level | $3.20 | $0.85 |
| Resistance Level | $3.88 | $2.74 |
| Average True Range (ATR) | 0.52 | 0.08 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 8.55 | 5.15 |
Price Performance
Historical ComparisonAbout BMHL Bluemount Holdings Limited Class B Ordinary Shares
Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.